


Ongoing and Planned PrEP Open Label, Demonstration and Implementation Projects, April 2019							 Global Advocacy for HIV Prevention
Trial/Project	Sponsor/Funder	Type/Category	Location	Population	Design/Key questions	Status	Status Details
DISCOVER	Gilead Sciences	Clinical Trial	USA, Canada, Austria, Denmark, France, Germany, Italy, Ireland, Netherlands, Spain, UK, Scotland	MSM, Transgender Women	Conducted by Gilead, the purpose of the trial is to assess whether F/TAF (trade name Descovy) is safe and effective as an oral daily HIV pre-exposure prophylaxis (PrEP) product. It is being compared with F/TDF (trade name Truvada), which is approved for use as PrEP in many countries and has already been proven safe and highly effective at reducing HIV acquisition.	Ongoing	Ongoing; started September 2016.
IPERGAY	Inserm-ANRS, the Canadian Trial network, Bill and Melinda Gates Foundation, Fondation Pierre Bergé, Gilead Sciences	Clinical Trial	Canada, France	MSM, Transgender Women	Evaluated "on demand" PrEP with Truvada versus placebo arm. The drug regimen involved taking Truvada in the 24-hour period before anticipated sex and then, if sex happened, two separate one-pill doses in the two days following sex. After the discontinuation of the placebo arm in October 2014, the study will continue open-label until end of June 2016.	Completed	Completed; no longer providing PrEP to former participants.
Prévenir (Prevent)	Inserm-ANRS	Implementation Project	France	MSM, Men, Women, Transgender men, Transgender women	Interventional HIV prevention strategy based on pre-exposure prophylaxis (PrEP) for people in the Île-de-France area (or Paris region) who don't have HIV but who are at high risk of becoming infected with HIV (MSM, transgender men and women, heterosexual men and women, sex workers, migrants) in combination with overall prevention services (community-based or educational counselling; addiction, social and psychological care; condoms and lubricating gel; clean injection equipment; sexually transmitted diseases (STD) screening and treatment; hepatitis A virus (HAV), hepatitis B virus (HBV) and hepatitis C virus (HCV) vaccinations and post-exposure treatment of HIV infection as soon as possible after diagnosis using an antiretroviral combination recommended by the French Guidelines on HIV treatment).	Ongoing	Ongoing; started May 2017. Expected completion October 2020.